Condition: Steroid Refractory GVHD · Sponsor: ReAlta Life Sciences, Inc.
This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-refractory.
This description comes directly from the study's public registry record.
Linda Dell, MBA · 201-675-4044 · ldell@realtals.com
Always discuss trial participation with your own doctor first.
| Site 1091 | Duarte, California, United States | Active Not Recruiting |
| Site 1343 | Los Angeles, California, United States | Active Not Recruiting |
| Site 1318 | Atlanta, Georgia, United States | Active Not Recruiting |
| Site 1068 | St Louis, Missouri, United States | Active Not Recruiting |
| Site 1100 | Cincinnati, Ohio, United States | Active Not Recruiting |
| Site 1382 | Columbus, Ohio, United States | Active Not Recruiting |
| Site 3242 | Freiburg im Breisgau, Germany | Recruiting |
| Site 3101 | Seville, SE, Spain | Recruiting |
| Site 3360 | Madrid, Spain | Recruiting |
| Site 3227 | Salamanca, Spain | Recruiting |
| Site 3101 | Seville, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06343792